PAVM - PAVmed Inc

PAVM - PAVmed Inc

https://www.pavmed.com

Recent News

Powered by Alpha Vantage

PAVmed ( PAVM ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 4 months, 2 weeks ago • score: 0.34

PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health - Lucid Diagnostics ( NASDAQ:LUCD ) , PAVmed ( NASDAQ:PAVM )

Benzinga • 6 months, 3 weeks ago • score: 0.02

LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - Lucid Diagnostics ( NASDAQ:LUCD ) , PAVmed ( NASDAQ:PAVM )

Benzinga • 1 year ago • score: 0.07

Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive ... - PR Newswire

PR Newswire • 1 year, 3 months ago • score: -0.13

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive ... PR ...

PAVmed Provides Business Update and First Quarter 2024 Financial Results

PR Newswire • 1 year, 4 months ago • score: 0.16

Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14th at 8:30 AM EDT

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

PAVmed Inc. is a medical device company in the United States. The company is headquartered in New York, New York.

52W High

$1.90

52W Low

$0.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.09

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

0.10

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.63

EV/Revenue (<3 favorable)

42.07

P/S (TTM) (<3 favorable)

9.58

P/B (<3 favorable)

0.75

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

18.43%

Institutions (25–75% balanced)

10.64%

Shares Outstanding

21,932,900

Float

14,930,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,020,000

Gross Profit (TTM)

-487,000

EPS (TTM)

4.41

Profit Margin (>10% good)

71.45%

Operating Margin (TTM) (higher better)

-785.83%

ROE (TTM) (>15% strong)

0.11%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.99

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—